Drug Combinations to Enhance Sensitivity and Circumvent Resistance

增强敏感性和规避耐药性的药物组合

• 批准号: 9985235
• 负责人: Jeffrey Wallace Tyner
• 金额: $ 38.24万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-30 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9985235
• 关键词: Administrator; Agreement; Automobile Driving; Budgets; Collaborations; Communication; Communities; Data; Drug Combinations; Drug resistance; Ensure; Evaluation; Intellectual Property; Leadership; Office of Administrative Management; Performance; Policies; Preparation; Progress Reports; Recommendation; Research; Resistance; Resource Sharing; Scientific Evaluation; Specimen; Time; TimeLine; Travel; data resource; data sharing; drug sensitivity; meetings; operation; tumor

PROJECT SUMMARY/ABSTRACT – Administrative Core The Administrative Core will provide leadership, scientific oversight, governance, and administrative support to our Drug Combinations to Circumvent Resistance-Drug Resistance and Sensitivity Center (D2CR-DRSC) to ensure effective operations, communication, internal and external collaborations, compliance and rigorous scientific evaluation of D2CR-DRSC projects. Co-PD/Contact PI Jeffrey Tyner and Co-PD/PI Brian Druker will serve as Co-Leaders of the Administrative Core and will be supported by a Scientific Operations Leader, Cristina Tognon; a Collaborations Manager, Pierrette Lo; and a Research and Finance Administrator, Sarah Bowden. The Specific Aims of the Administrative Core are to: 1) provide scientific and administrative leadership, governance, and support to the D2CR-DRSC to ensure effective integration of all projects, evaluation of center progress, sharing of specimens and data, and internal communication and operational performance, and 2) provide scientific and administrative leadership to optimize the D2CR-DRSC’s communication and collaborations with the Drug Resistance and Sensitivity Network to ensure productive participation in cross-DRSC, NCI activities and the research community. To achieve these aims, the Administrative Core will establish and implement D2CR-DRSC governance, including establishing an Internal Advisory Group and an External Advisory Board to help evaluate the Center’s progress toward its aims and milestones; develop and follow policy to ensure timely release and sharing of specimens and data; plan regular strategic interactions and meetings; develop communications plans; ensure budget oversight and compliance; manage intellectual property issues; complete annual progress reports; facilitate communication, collaboration and data and resource sharing with the NCI, the DRSC Steering Committee, and the four other DRSCs in the Network; and perform all other administrative duties required to support the D2CR-DRSC and its successful participation in the Drug Resistance and Sensitivity Network.

项目摘要/摘要 – 行政核心 行政核心将提供领导、科学监督、治理和行政支持 我们的药物组合规避耐药性-耐药性和敏感性中心 (D2CR-DRSC) 确保有效的运营、沟通、内部和外部协作、合规和严格 D2CR-DRSC 项目的科学评估将由 Co-PD/Contact PI Jeffrey Tyner 和 Co-PD/PI Brian Druker 进行。 作为行政核心的联合领导者，并将得到科学运营领导者的支持， Cristina Tognon；合作经理 Pierrette Lo；以及研究和财务管理员 Sarah 鲍登。行政核心的具体目标是：1）提供科学和行政服务。 对 D2CR-DRSC 的领导、治理和支持，以确保所有项目的有效整合， 评估中心进展、共享标本和数据以及内部沟通和运营 绩效，2) 提供科学和行政领导，以优化 D2CR-DRSC 的 与耐药性和敏感性网络的沟通和合作，以确保生产力 参与跨 DRSC、NCI 活动和研究界的活动 为了实现这些目标， 行政核心将建立并实施 D2CR-DRSC 治理，包括建立内部 咨询小组和外部咨询委员会帮助评估中心实现其目标的进展情况 里程碑；制定并遵循政策，确保定期发布和共享样本和数据； 战略互动和会议；制定沟通计划；确保预算监督和合规性； 管理知识产权问题；完成年度进度报告；促进沟通、协作； 与 NCI、DRSC 指导委员会以及其他四个 DRSC 共享数据和资源 网络；并履行支持 D2CR-DRSC 及其成功所需的所有其他管理职责 参与耐药性和敏感性网络。